INNOCARE Aktie

 

InnoCare Optoelectronics is expanding its global service network to capture growth from rising regional economies. Chairman James Yang said the company has entered India with localized manufacturing to reduce tariff barriers while addressing demand for healthcare digitalization. In the Americas, InnoCare has established local repair centers to provide immediate technical support and after-sales services, strengthening customer service and market share across regional markets....

InnoCare's next-generation TRK inhibitor Zurletrectinib receives priority review for the treatment of pediatric patients with solid tumors in China....

InnoCare announced key clinical development progress, including the completion of patient enrollment of multiple Phase III registrational trials....

The current indications of soficitinib under development are strategically positioned within the vast dermatology market....

ICP-538 is the first VAV1 degrader approved to enter clinical trials in China and the second globally....

For the year ended 31 December 2025, INNOCARE (09969.HK) expected to achieve a total operating revenue of approx. RMB2.365 billion, representing a YoY increase of approx. 134%, as announced by INNOCARE. The Company expected to turn from loss to profit for the first time in 2025. The net profit attributable to owners of the paren......

CLE is the second indication InnoCare is developing for ICP-488, and enrollment for the phase III study of ICP-488 for psoriasis is nearing completion....

The current indications under development are strategically positioned within the vast dermatology market, including AD, vitiligo, PN, CSU, and more....

InnoCare Optoelectronics held an investor conference on December 16, 2025, where company chairman James Yang pointed out that while the global medical device market grows annually by about 5–8%, InnoCare maintains a double-digit growth rate, outperforming the overall market. The company expects to sustain stable growth through 2026....

- Orelabrutinib is the first BTK inhibitor to demonstrate significant clinical activity in a Phase 2 clinical trial for SLE -...

Orelabrutinib demonstrated outstanding efficacy and well-tolerated safety profile in patients with SLE who had received 48 weeks of treatment....

In the registrational clinical trial, zurletrectinib demonstrated outstanding efficacy and a favorable safety profile, with ORR of 89.1% and DCR of 96.4%....

Orelabrutinib has demonstrated remarkable efficacy and safety in multiple lymphoma studies, including MZL, MCL, CLL/SLL, PCNSL and DLBCL....

The study of mesutoclax in the treatment of r/r MCL was selected for oral presentation, while the CLL/SLL and AML studies were chosen for poster....

InnoCare's pipeline under development now covers ten major autoimmune diseases, with a particular focus on dermatological conditions....

UBS released a China market strategy report, listing Buy-rated names with the highest potential FY26 earnings upside for Chinese stocks. The following list only includes Hong Kong-listed and ADR-listed Chinese stocks:Stocks:INNOCARE (09969.HK)CARSGEN-B (02171.HK)ZAI LAB (09688.HK)AKESO (09926.HK)ECARX Holdings (ECX.US)CANSINOBIO......

ICP-B794 has demonstrated superior anti-tumor activity in animal models, and exhibited significant tumor-killing effects even in large tumors....

Zurletrectinib demonstrated well-tolerated safety and promising antitumor activity in pediatric/adolescent patients with NTRK/ROS1-altered solid tumors....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

INNOCARE (09969.HK) announced that InnoCare, its wholly-owned subsidiary incorporated in the US, has entered into an exclusive license agreement and a subscription agreement with Zenas (ZBIO.US) for the development, manufacture, and commercialization of orelabrutinib and two other preclinical assets.Under the terms of the licens......